Search Results - "Monge Escartin, I."

4CPS-014 Comparison of two protocols for the administration of leucovorin rescues after high dose methotrexate infusion of 24 hours by Escolà Rodríguez, A, Arranz Pasqual, N, Bastida, C, Albanell, M, Monge Escartín, I, Maté Arbaiza, P, Ruiz Boy, S, Carcelero San Martín, E, Soy Muner, D

“…Background and ImportanceTherapeutic drug monitoring (TDM) of methotrexate (MTX) in plasma is a standard procedure to early identify patients with delayed drug…”
Get full text

975P Impact of body mass index on the efficacy of immune checkpoint inhibitors in cancer by Rios Hoyo, A., Hardy-Werbin, M., Monzonís, X., Monge Escartin, I., Moliner, L., Navarro, N., Taus, Á., Durán, X., Conde, D., Arriola, E.

Get full text

CP-180 Reasons for switching from integrase inhibitors in a real cohort of hiv patients during a 3 year study by Antonio-Cuscó, M De, Luque, S, González-Colominas, E, Ferrández, O, Monge-Escartin, I, Knobel, H, Salas, E

“…BackgroundIntegrase inhibitors (INSTIs) are recommended as firstline antiretroviral treatment (ART) in HIV patients. However, several factors such as toxicity,…”
Get full text